Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Atara Biotherapeutics Inc
ATRACurrent price
9.47 USD
-0.43 USD (-4.34%)
Last closed
10 USD
Company
www.atarabio.com
ISIN
US0465131078
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
37 354 380 USD
Yield for 12 month
-75.40 %
1Y
3Y
5Y
10Y
15Y
ATRA
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
90.5 USDP/E ratio
–Dividend Yield
–Current Year
+8 573 000 USD
Last Year
+63 573 000 USD
Current Quarter
+28 640 000 USD
Last Quarter
+27 357 000 USD
Current Year
-313 000 USD
Last Year
+49 005 000 USD
Current Quarter
+24 013 000 USD
Last Quarter
+25 372 000 USD
Key Figures ATRA
1 year
3 years
5 years
10 years
EBITDA
-162 124 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-57.48 %
PEG Ratio
–
Return On Equity TTM
-2014.86 %
Wall Street Target Price
90.5 USD
Revenue TTM
62 387 000 USD
Book Value
-22.61 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
2892.7 %
Dividend Yield
–
Gross Profit TTM
63 573 000 USD
Earnings per share
-39 USD
Diluted Eps TTM
-39 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-290.2 %
Dividend Analytics ATRA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:25
Payout Ratio
–
Last Split Date
20.06.2024
Dividend Date
–
Stock Valuation ATRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.877
Price Sales TTM
0.5988
Enterprise Value EBITDA
-0.3471
Price Book MRQ
1.9674
Financials ATRA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATRA
For 52 weeks
4.97 USD
49 USD
50 Day MA
8.61 USD
Shares Short Prior Month
360 528
200 Day MA
14.41 USD
Short Ratio
7
Shares Short
378 453
Short Percent
7.81 %
BeatStart